Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

NCT02052648 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma Multiforme
Glioma
Gliosarcoma
Malignant Brain Tumor

Interventions

DRUG: Indoximod
DRUG: Temozolomide
DRUG: Bevacizumab
RADIATION: Stereotactic Radiation

Sponsor

NewLink Genetics Corporation